Melbourne, Australia:  Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) will today present to institutional fund managers at the Goldman Sachs Emerging Companies conference in Sydney.

The invitation-only event involves 35 companies across all sectors.  Starpharma is one of three healthcare companies invited to attend - the other two are Blackmores and Sigma Pharmaceuticals.

The presentation will provide an overview of the company, including highlighting:

• Starpharma’s portfolio approach across the pharmaceutical, women’s health and agrochemical industries, and the expanding number of advanced products nearing commercialisation;
• Starpharma’s lead product, VivaGel^® for the management of bacterial vaginosis including the first-in-class prevention of recurrence product, commercial progress and symptomatic relief;
• the VivaGel^® coated condom product currently under regulatory review and already licensed to Ansell and Okamoto;
• Drug delivery, including Starpharma’s dendrimer-docetaxel nanoparticle formulation; and
• the Agrochemical program, including the recent partnership with Makhteshim Agan.

Download ASX Announcement: Starpharma presenting at Goldman Sachs Emerging Companies Conference ( pdf file, 2MB)